Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of EGCG palmitate in preparing medicines for treating or preventing human enterovirus 71 infection

A palmitate, enterovirus technology, applied in antiviral agents, drug combinations, digestive systems, etc., can solve the problems of prevention and treatment that have not yet been mentioned and applied, and achieve high yield, convenient material acquisition, and convenient use. Effect

Inactive Publication Date: 2014-10-15
武汉胜达康生物科技有限公司
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the inhibitory effect of EGCG and its derivatives on influenza virus has been studied and mentioned, the prevention and treatment of enterovirus 71 (EV71), which is more prevalent and highly pathogenic, has not been mentioned and applied yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of EGCG palmitate in preparing medicines for treating or preventing human enterovirus 71 infection
  • Application of EGCG palmitate in preparing medicines for treating or preventing human enterovirus 71 infection
  • Application of EGCG palmitate in preparing medicines for treating or preventing human enterovirus 71 infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 Toxicity determination of EGCG palmitate to host cells

[0039] When the RD cells cultivated for 24-48 hours are almost covered with a single layer, discard the cell culture medium, add trypsin to digest, transfer to a 96-well sterile cell culture plate, 100 μl per well (1*10 5 cell / ml, the same below). Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. Discard the culture medium, dilute the EGCG palmitate stock solution with cell culture medium, and configure five concentration gradients, add different concentrations of drugs into the cell culture wells, 100 μl per well, repeat 3 wells for each concentration, and at the same time Set up cell control wells (do not add drugs, only add cell culture medium), add 100 μl of cell culture medium to each well, and place in a cell culture incubator at 37°C. The toxicity test method of Pleconaril (positive control drug) and DMSO and EGCG palmitate is the same...

Embodiment 2

[0043] Embodiment 2 EV71 is to the mensuration of cell half infection dose (TCID50)

[0044] Transfer the RD cells cultured into a single layer to a 96-well cell culture plate, and place them in a cell culture incubator for 18-24 hours. The virus stock solution was serially diluted 10 times with cell maintenance solution (10 -1 -10 -8 ). Discard the cell culture medium in each well of the RD cultured into a single layer, wash each well with PBS 3 times, add 100 μl of virus dilution solution of different concentrations to each well, absorb at 37°C for 1.5 h, discard the virus dilution solution, and replenish each well. Add 100 μl of cell maintenance solution, 10 replicates for each concentration, and set normal cell control wells (without adding virus). The cytopathic effect (CPE) of each well was observed daily for 3 consecutive days, and the CPE situation was recorded. The titer of the virus was then calculated by the Reed-Muench method. The following is the calculation ...

Embodiment 3

[0048] Example 3 The preventive effect of EGCG palmitate on EV71 virus

[0049] When the RD cells cultured for 24-48 hours are almost covered with a monolayer, the cell culture medium is discarded, digested with trypsin, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. Discard the cell culture medium, and dilute the EGCG palmitate stock solution with the cell culture medium to form three concentration gradients required for the experiment. After dilution, add different concentrations of drugs into the cell culture wells, 100 μl per well, each The concentration was repeated for 3 wells, and a cell control well (no virus, no drug, only cell culture medium) and a virus control well (no drug, virus, and culture medium) were set up at the same time, and Pleconaril was used as a positive control drug. After drug incubation for 1 h, discard the supe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of novel applications of medicines and particularly discloses an application of EGCG palmitate in preparing the medicines for treating or preventing human enterovirus 71 (EV 71) infections. The invention testifies that the EGCG palmitate has favorable antivirus action in EV 71 infection cell test in vitro and the EV 71 infection can be prevented; compared with the positive control medicine Pleconaril, the efficacy of the EGCG palmitate is more remarkable, which shows that the medicine has the prospect of being developed into the medicines to resist EV 71.

Description

technical field [0001] The invention relates to the technical field of new medical applications, and more specifically relates to the application of EGCG (epigallocatechin gallate) palmitate in the preparation of medicines for treating or preventing enterovirus 71 (EV71) infection. Background technique [0002] Enterovirus 71 (human enterovirus 71, EV71) is a member of the Picornaviridae Enterovirus genus, which was first isolated in 1969 from fecal samples of infants with central nervous system diseases in California. Usually EV71 infection can cause HFMD, which is mild and mostly self-limiting, which is indistinguishable from HFMD caused by Coxsackie A16. In addition, EV71 can also cause aseptic meningitis, brainstem encephalitis, acute flaccid paralysis, acute cardiopulmonary dysfunction and other serious neurological diseases, and even death. In recent years, EV71 has repeatedly caused disease outbreaks or epidemics worldwide, such as the Sarawak region of Malaysia in 1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/353A61P31/14A61P1/00
Inventor 吴建国徐德邬开朗孙师刘映乐潭秋萍刘芳
Owner 武汉胜达康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com